Accelerate to Discover
Related topics
B fibers are the best predictors of cardiac activity during Vagus nerve stimulation
Jul 17, 2018
Vagus nerve stimulation (VNS) is a promising therapy for many neurologic and psychiatric conditions. However,...
Webinar Tuning Microenvironment to Control Cells for Improved Disease Modeling & Immunotherapy Work
Jul 16, 2018
The company producing Avatar, xCELL biosciences have organized a webinar about the tuning of microenvironment to...
New technologies to uncover the molecular basis of disorders of sex development
Jul 13, 2018
Newer approaches, such as whole-genome sequencing and whole-genome mapping have the potential to identify novel...
δT cells and CD8+ T cells targeting of breast cancer cells
Jul 11, 2018
Cancer stem cells (CSCs) are a large cause of metastasis in breast cancer. They are also very resistent to any...
Incucyte system used for generating single-cell-derived cancer-associated fibroblast clones
Jul 9, 2018
Single-cell-derived cancer-associated fibroblast (CAFs) were produced using Incucyte. These cells were used to help...
Real-time verification of clonality using IncuCyte system
Jun 28, 2018
Use whole-well, label-free imaging to automatically scan for clones and verify monoclonality. Integrated image...
First DLS paper: Sorghum genome assembled with nanopore sequencing and DLS
Jun 26, 2018
The new paper describes a chromosome-scale de novo assembly of the repeat-rich Sorghum bicolor Tx430 genome built using...
NovoCyte Quanteon - when exceptional performance meets simplicity
Jun 21, 2018
NovoCyte Quanteon system is the answer for growing demands in modern flow-cytometry assays. With its four lasers (405,...
May 18, 2016
With the increasing need for new therapies for cancer, autoimmune disorders and Alzheimer’s disease, monoclonal antibodies are proving very successful due to their high affinity and specificity for their target antigens. In cancer, for example, their first use was as antagonists of oncogenic receptor tyrosine kinases, but today monoclonal antibodies have emerged as vehicles for the targeted delivery of potent chemotherapeutic agents and as powerful tools to manipulate anticancer immune responses. Currently,
more than 30 antibody therapeutics are marketed worldwide. Some analysts predict that, given the rate of current revenue growth and potential new approvals, the global market could reach $58 billion by 2016. In addition, there are hundreds of monoclonal antibody-based biologic drugs in various phases of clinical trials worldwide.
Get more info
Brand profile
IntelliCyt Corporation's high throughput flow technology is the first to enable screening suspension cells, beads, microbes and mixtures.
More info at:
www.intellicyt.com/
BioFocus newsletter
Register to receive Brand new technology development, Important product updates, Interesting scientific events and more!
BioTech a.s. © 2014
Designed & developed by imagineit
Technologies
